Government puts curbs on export of Enoxaparin
"The export of Enoxaparin (formulation and API) and intra-venous immunoglobulin (formulation and API) ....has been put under restricted category with immediate effect," the Directorate General of Foreign Trade (DGFT) said in a notification. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2022 Category: Pharmaceuticals Source Type: news

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping
Princeton, NJ, Sandoz Inc. ( “Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injectio (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 2, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cadila inks pact with Italian firm to launch generic product in US
The partners plan to launch the product which is a generic version of Sanofi Aventis's Lovenox (Enoxaparin Sodium Injection) in seven dosage strengths in the US, the statement said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2021 Category: Pharmaceuticals Source Type: news

Abelacimab Prevents VTE After Total Knee Arthroplasty
Single, postoperative IV dose of abelacimab superior to enoxaparin for preventing venous thromboembolism, with no increase in bleeding risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Surgery, Conference News, Source Type: news

DDMA asks pharmacies to display available stock, cost of COVID-19 drugs prominently
The drugs are Ivermectin tablets, Doxycyclin tablets/capsule, Methyl Prednisolone tablets and injections, Dexamethasone tablets and injections, Budosenide Inhalers and Respules Favipiravir tablets, Apixaban tablets and Enoxaparin Sodium/ Clexane, it said. (Source: The Economic Times)
Source: The Economic Times - May 22, 2021 Category: Consumer Health News Source Type: news

Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL stre (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

India considers allowing import of raw material for manufacturing crude heparin
Heparin and its related derivative, the low molecular weight heparin, also known as enoxaparin, is an anticoagulant that has demonstrated its effectiveness in treatment of patients infected with Covid-19 virus during the ongoing pandemic. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2020 Category: Pharmaceuticals Source Type: news

What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients?, CEBM
This study identified a paucity of evidence for both the risks factors of VTE and the effectiveness of prophylactic strategies to prevent VTE in COVID-19 patients. Potential risk factors which were identified for thrombolytic events include older age and higher levels of D-dimer, though the actual threshold for a high level D-dimer varied between studies. Commonly encountered prophylactic strategies which were; low molecular weight heparin (LMWH) or unfractionned heparin, nadroparin and enoxaparin. A number of studies found that despite prophylaxis there was still a high incidence of thrombolytic complications in COVID-1...
Source: Current Awareness Service for Health (CASH) - July 13, 2020 Category: Consumer Health News Source Type: news

Enoxaparin in acute coronary syndromes: better outcomes, lower cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

Rivaroxaban Prevents VTE After Lower - Limb Surgery
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 3, 2020 Category: Respiratory Medicine Tags: Internal Medicine, Emergency Medicine, Oncology, Orthopedics, Pharmacy, Pulmonology, Surgery, Journal, Source Type: news

Rivaroxaban Prevents VTE After Lower-Limb Surgery
FRIDAY, April 3, 2020 -- Following nonmajor orthopedic surgery of the lower limb, rivaroxaban is superior to enoxaparin for prevention of major venous thromboembolism, according to a study published online March 29 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2020 Category: Pharmaceuticals Source Type: news

PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis
New trial results show rivaroxaban was not only noninferior but superior to enoxaparin in reducing venous thromboembolism after nonmajor orthopedic surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

29.03.20: Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgeryData from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different be...
Source: Bayer IR Newsfeed: Events - March 28, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news